Evidence map›Paper›PMID 39955592›Full record

ArticleBMC veterinary research2025

An extensively hydrolysed protein-based extruded diet in the treatment of dogs with chronic enteropathy and at least one previous diet-trial failure: a pilot uncontrolled open-label study.

Valérie Freiche, Olivier Dossin, Amélie Leclerc, Isabelle Mougeot, Jeremy Laxalde, Olivier Roy, Vincent Biourge, Alexander J German

Abstract readMulticenter StudyClinical Trial, Veterinary
In one paragraph

Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. The alleviating effects and mechanisms ofFrontiers in veterinary science · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Valérie FreicheUnité de médecine interne, Ecole Nationale Vétérinaire d'Alfort, CHUVA, Maisons-Alfort, France.
Olivier DossinADVETIA, Small Animal Internal Medicine, Velizy-Villacoublay, 78140, France.
Amélie LeclercCentre Vétérinaire Daubigny, Québec, Canada.
Isabelle MougeotSymrise, Elven, France.
Jeremy LaxaldeRoyal Canin Research & Development, Aimargues, France.
Olivier RoyCebiphar, Fondettes, 37230, France.
Vincent BiourgeRoyal Canin Research & Development, Aimargues, France.
Alexander J GermanInstitute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. ajgerman@liverpool.ac.uk.

Funding

Royal Canin N/A
6 · The paper itself

Abstract

backgroundCanine chronic enteropathies (CE) are a group of disorders defined by persistent or recurrent clinical signs of gastrointestinal disease without a primary neoplastic, metabolic, parasitic, or other infectious cause. In this prospective, multicentre, uncontrolled, open-label study, a commercial dry diet with a protein source of extensively hydrolysed poultry feather was assessed in the management of dogs with CE that had not responded to previous dietary and antibacterial therapies. Dogs with moderate or marked protein-losing enteropathy were excluded. After screening, dogs entered stage 1 and started the test diet. Gastrointestinal endoscopy was performed, and only dogs with histopathological evidence of small intestinal inflammation confirming CE could continue to stage 2 of the trial. The test diet was fed for 10 weeks throughout stages 1 and 2, and the primary outcome measure was clinical success defined as a reduction in canine inflammatory bowel disease activity index (CIBDAI) of ≥ 75%. Secondary outcomes included body condition score (BCS, scale 1-9) and faecal consistency score (scale 1-5). Results (median [range]) for dogs with confirmed CE that participated in both study stages are reported.

resultsA total of 15 dogs commenced stage 1, and 13 of these progressed to stage 2 (age 4.2 [1.1-7.1] years; BCS 3 (2-4); previous diet therapies 2 [1-3]) of which two were withdrawn at week 5 for protocol deviations. CIBDAI scores decreased from 9 (7-16; n = 13) at baseline to 2 (1-11; n = 13) at week 2 (P < 0.001), 2 (0-6; n = 13) at week 5 (P < 0.001), and 1 (0-3; n = 11) at week 10 (P < 0.001). Treatment success was achieved by 8/13 dogs at week 5 and 10/11 dogs at week 10. Faecal score (n = 11) and BCS (n = 11) improved between baseline (1 [1-3] and 3 [3-4], respectively; P < 0.001) and week 10 (4 [3-5] and 4 [3-5], respectively; P < 0.001).

conclusionsDogs with CE that had failed to respond to previous dietary and antibacterial therapy showed clinical improvement within 10 weeks when fed a dry extruded diet with a single protein source hydrolysed to amino acids and oligopeptides, without concurrent immunosuppressant treatment.

Indexed as

Dog DiseasesIntestinal DiseasesProtein HydrolysatesAnimal FeedAnimalsChronic DiseaseDietDietary ProteinsDogsFemaleMalePilot ProjectsProspective StudiesDietary ProteinsProtein HydrolysatesAmino acidsChronic diarrhoeaFood-responsive enteropathyHypoallergenicInflammatory bowel diseaseNutritionOligopeptideProtein hydrolysate

Identifiers

PMID39955592
PMCPMC11830179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.